Efgartigimod for treating Guillain-Barré syndrome
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new medicine called efgartigimod for people with Guillain-Barré syndrome (GBS), a condition where the immune system attacks the nerves. The medicine aims to reduce the immune attack and help you recover faster. It is for people who started having GBS symptoms within the last 2 weeks and have moderate to severe symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with Guillain-Barré syndrome (GBS) by a doctor.
- Your GBS symptoms started within the last 2 weeks.
- Your GBS symptoms are moderate to severe (score of 3 to 5 on a disability scale).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study, and if you could become pregnant, you agree to use effective birth control.
- You have not had a live vaccine in the last 4 weeks and do not plan to get one during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational medicine called empasiprubart when added to the standard IVIg treatment for people with Guillain-Barré syndrome. It aims to see if adding this medicine can help improve recovery compared to IVIg alone.
This is an observational study that looks at people who were suspected to have Guillain-Barré syndrome and were cared for at University Hospital of Basel in the past. It does not test a new treatment—researchers review existing care to learn more about this condition.
This trial tests whether an experimental drug called efgartigimod (given as an infusion) can help people with Guillain-Barré syndrome recover faster. It is for adults who recently developed symptoms and have significant weakness that affects their walking.
This trial compares two blood-based treatments for Guillain-Barré syndrome: one that filters antibodies from the blood (immunoadsorption) and one that uses donated antibodies (IVIG). Both aim to reduce nerve damage and speed up recovery, and researchers want to see which works better.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
Hear when a new Guillain-Barre Syndrome (GBS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.